RXSIGHT NOTICE: BFA Law Notifies RxSight, Inc. Investors of the Pending Securities Fraud Class Action – Contact BFA Law if You Lost Money (NASDAQ:RXST)

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Issues - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors who purchased RxSight securities [2]. - The complaint highlights that RxSight failed to disclose "adoption challenges" and experienced a slowdown in LAL utilization, first noted in 2024 [4]. Group 3: Stock Performance - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, leading to a stock price drop of approximately 38%, from $26.12 to $16.21 per share [5]. - Following another revenue forecast cut on July 8, 2025, the stock price fell roughly 38% again, from $12.79 to $7.95 per share [6].